Handbuch ADHS. Группа авторов

with adverse childhood environment. Psychiatry Res 158(2): 123–31.

      Riikonen RS, Nokelainen P et al. (2005). Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-beta-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry. Biol Psychiatry 57(12): 1565–72.

      Roessner V, Walitza S et al. (2007). Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD? Behav Brain Funct 3(1): 64.

      Roessner V, Manzke T et al. (2009a). Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD. World J Biol Psychiatry 26(1):1–5.

      Roessner V, Sagvolden T et al. (2009a). MPH treatment normalizes elevated dopamine transporter density in an animal model of ADHD (submitted).

      Ruskin DN, Bergstrom DA et al. (2001). Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol Psychiatry 49(4): 340–50.

      Russell VA (2002). Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder– the spontaneously hypertensive rat. Behav Brain Res 130(1–2): 191–6.

      Russell VA, Sagvolden T et al. (2005). Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 1: 9.

      Sagvolden T, Johansen EB et al. (2005). A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28(3): 397–419; discussion 419–68.

      Schiffer WK, Volkow ND et al. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59(4): 243–51.

      Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AL, Rapoport JL (2009). Psychostimulant Treatment and the developing cortex in attention deficit hyperactivity. Am J Psychiatry 166(1): 58–63.

      Shaywitz BA, Cohen DJ et al. (1977). CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. A preliminary report. J Pediatr 90(1): 67–71.

      Sheehan K, Lowe N et al. (2005). Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 10(10): 944–9.

      Sheehan K, Hawi Z et al. (2007). No association between TPH2 gene polymorphisms and ADHD in a UK sample. Neurosci Lett 412(2): 105–7.

      Shekim WO, Bylund DB et al. (1986). Platelet MAO and measures of attention and impulsivity in boys with attention deficit disorder and hyperactivity. Psychiatry Res 18(2): 179–88.

      Shetty T, Chase TN (1976). Central monoamines and hyperkinase of childhood. Neurology 26(10): 1000–2.

      Sikstrom S, Soderlund G (2007). Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol Rev 114(4): 1047–75.

      Solanto MV (2002). Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130(1–2): 65–71.

      Spivak B, Vered Y et al. (1999). Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99(4): 300–4.

      Tripp G, Wickens JR (2008). Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. J Child Psychol Psychiatry 49(7): 691–704.

      Volkow ND, Ding YS et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52(6): 456–63.

      Volkow ND, Wang G et al. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21(2): RC121.

      Walitza S, Renner TJ et al. (2005). Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 10(12): 1126–32.

      Watanabe Y, Fujita M et al. (1997). Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38(3): 470–4.

      Wilens TE (2008). Effects of Methylphenidate on the Catecholaminergic Sytstem in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmcaol 28 (Suppl. 2): S46–S53.

      Williams J (2008). Working toward a neurobiological account of ADHD: commentary on Gail Tripp and Jeff Wickens, dopamine transfer deficit. J Child Psychol Psychiatry 49(7): 705–11; discussion 711.

      Yano M, Steiner H (2005). Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132(3): 855–65.

      Zhang K, Davids E et al. (2002). Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res 137(2): 135–8.

4 Noradrenalin wird international i. d. R. als Norepinephrin benannt, weswegen hier auch die Abkürzung NE benutzt wird.